Related Experiment Video
Updated: Apr 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Systemic Regulation of RAS/MAPK Signaling by the Serotonin Metabolite 5-HIAA
Tobias Schmid1, L Basten Snoek2, Erika Fröhli3
1University of Zurich, Institute of Molecular Life Sciences, Zurich, Switzerland; PhD Program in Molecular Life Sciences, University and ETH Zurich, Zurich, Switzerland.
Abstract:
Human cancer is caused by the interplay of mutations in oncogenes and tumor suppressor genes and inherited variations in cancer susceptibility genes. While many of the tumor initiating mutations are well characterized, the effect of genetic background variation on disease onset and progression is less understood. We have used C. elegans genetics to identify genetic modifiers of the oncogenic RAS/MAPK signaling pathway. Quantitative trait locus analysis of two highly diverged C. elegans isolates combined with allele swapping experiments identified the polymorphic monoamine oxidase A (MAOA) gene amx-2 as a negative regulator of RAS/MAPK signaling. We further show that the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), which is a product of MAOA catalysis, systemically inhibits RAS/MAPK signaling in different organs of C. elegans. Thus, MAOA activity sets a global threshold for MAPK activation by controlling 5-HIAA levels. To our knowledge, 5-HIAA is the first endogenous small molecule that acts as a systemic inhibitor of RAS/MAPK signaling.
Insights
Genetic background influences cancer by modifying oncogenic pathways. In C. elegans, monoamine oxidase A (MAOA) activity regulates the RAS/MAPK pathway via the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA).
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- Human cancer arises from mutations in oncogenes, tumor suppressor genes, and inherited variations.
- The influence of genetic background on cancer onset and progression remains incompletely understood.
- The RAS/MAPK signaling pathway is frequently implicated in oncogenesis.
Purpose of the Study:
- To identify genetic modifiers of the oncogenic RAS/MAPK signaling pathway using C. elegans.
- To elucidate the role of genetic background in regulating pathway activity.
- To discover novel endogenous regulators of RAS/MAPK signaling.
Main Methods:
- Utilized C. elegans genetics for modifier screening.
- Performed quantitative trait locus (QTL) analysis on diverged C. elegans isolates.
- Conducted allele swapping experiments to validate gene function.
- Measured levels of serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA).
Main Results:
- Identified the monoamine oxidase A (MAOA) gene, specifically amx-2, as a negative regulator of RAS/MAPK signaling.
- Demonstrated that 5-hydroxyindoleacetic acid (5-HIAA), a product of MAOA, acts as a systemic inhibitor of RAS/MAPK signaling.
- Established that MAOA activity modulates 5-HIAA levels, thereby setting a global threshold for MAPK activation.
Conclusions:
- MAOA and its metabolite 5-HIAA are critical endogenous regulators of RAS/MAPK signaling.
- MAOA activity provides a systemic mechanism to control MAPK pathway activation.
- This study identifies 5-HIAA as the first known endogenous small molecule inhibitor of RAS/MAPK signaling.
Related Concept Videos
MAPK Signaling Cascades
The Ras Gene
Ras is a...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway

